Stock AnalizPediatrix Medical Group, Inc. MD
Hospital/Nursing Management · data as of November 13, 2026
Pediatrix Medical Group, Inc. (MD) is a healthcare company listed in the US with a market value of about $2.4B. In the twelve months to September 30, 2026 it had revenue of $2.0B and net income of $150M, a net margin of 7.7%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is value (3/5); the weakest is track record (1/5).
Key numbers: a P/E of 17.0, a price to free cash flow of 11.7, 5-year revenue growth of 2% a year, a 5-year average ROIC of 5%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 39% below the current price.
Score: 2.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- ROE above 15%
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0B | $1.9B | $2.0B | $2.0B | $2.0B | $1.9B | $1.7B | $1.8B | $1.7B | $3.5B | $3.2B |
| Net income | $150M | $165M | -$99M | -$60M | $66M | $131M | -$796M | -$1.5B | $269M | $320M | $325M |
| Free cash flow | $210M | $253M | $185M | $104M | $137M | $44M | $176M | $338M | $297M | $485M | $405M |
| EPS (diluted) | $1.84 | $1.94 | $-1.19 | $-0.73 | $0.79 | $1.53 | $-9.55 | $-17.83 | $2.93 | $3.45 | $3.49 |
| Net margin | 7.7% | 8.6% | -4.9% | -3.0% | 3.4% | 6.9% | -45.9% | -84.2% | 15.6% | 9.3% | 10.2% |
| ROIC | — | 10.6% | -4.7% | 0.4% | 8.3% | 8.3% | 3.1% | 3.8% | 3.6% | 7.3% | 8.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $30.08, 4% below the current price; targets range from $28.00 to $33.50; the consensus rating is “Hold”; expected EPS is $2.40 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Pediatrix Medical Group’s P/E ratio?
About 17.0, based on the last twelve months of diluted earnings per share (forward P/E about 13.4).
Is Pediatrix Medical Group stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 39% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Pediatrix Medical Group pay a dividend?
Not currently.
Is Pediatrix Medical Group a good stock to buy?
We do not give buy or sell advice. Pediatrix Medical Group scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.